CHINA NEXT WINNERS Innovative growth companies in strategic sectors will emerge as China Next Winners. See Disclosure Appendix of this report for important disclosures and analyst certifications Published: 27 Oct 2025 03:59 UTC | Revised 27 Oct 2025 03:59 UTC OCTOBER 2025 October 27, 2025 CHINA NEXT WINNERS 1 2 CHINA NEXT WINNERS PORTFOLIO MANAGER'S SUMMARY China's five-year plans have long served as roadmaps for investors, enabling them to focus on key sectors at the center of policy. History shows that th ...

PresentationI will now turn the call over to Karin Hellsvik, Vice President of Investor Relations and Corporate Affairs. Please go ahead.Welcome to the Foghorn Pipeline Update Conference Call. [Operator Instructions] As a reminder, this webcast is being recorded today, October 30, 2025.Karin HellsvikChief of Staff to the CEO, VP of Corporate Affairs & Investor Relations Thank you, everyone, for joining us today. This is Karin Hellsvik, Vice President of Investor Relations and Corporate Affairs for Foghorn. ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:Guggenheim 2nd Annual Healthcare Innovation Conference DATE:Wednesday, November 12, 2025 TIME:9:00am ET W ...

Intensity Therapeutics, Inc (INTS) - 公司股价大幅上涨435.63%至1.42美元，交易量超过11亿股，显示市场关注度极高 [2] - 核心产品INT230-6处于二期临床试验阶段，并与默克和百时美施贵宝合作评估联合疗法 [2] - 一期/二期IT-01临床研究结果在《eBioMedicine》发表，其专有非共价药物偶联技术展示治疗转移性或难治性癌症潜力 [2] Harvard Bioscience, Inc (HBIO) - 公司股价上涨101.19%至0.89美元 [3] - 公司为制药、生物技术公司、大学及政府实验室的研究科学家开发和生产用于基础研究和临床前测试的技术、产品及服务 [3] - 市场关注其将于2025年11月6日发布的2025年第三季度财务业绩 [3] NextPlat Corp - 公司股价上涨62.5%至0.13美元 [4] - 业务专注于为商业、政府、军事及人道主义组织提供移动卫星服务解决方案，包括语音、数据、物联网连接等 [4] - 公司向Web3和数字资产领域的拓展增强了投资者信心 [4] Shineco, Inc (SISI) - 公司股价上涨59.38%至1.02美元 [5] - 公司业务为加工和分销源自中国本土植物的特种面料、纺织品及其他副产品，并结合科学方法融合传统东方医药 [5] - 公司宣布一项870万美元的技术交易及在新加坡的重大联盟，预计将推动增长 [5] Jasper Therapeutics, Inc - 公司股价上涨49.36%至0.11美元 [6] - 作为临床阶段生物技术公司，专注于开发用于造血干细胞移植和基因疗法的治疗药物 [6] - 其主要候选产品briquilimab在干细胞移植和基因疗法的新型预处理方案中具备潜力 [6]

Meta CEO Mark Zuckerberg on stage at the Meta Connect conference in September. David Paul Morris / Bloomberg via Getty Images Close Key Takeaways Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine maker's shares shoot higher. Chipotle Mexican Grill (CMG) stock fell 18.2%, the most of any S&P 500 component, after the fast-casual burrito chain reported lower-tha ...

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences: TD Cowen's Immunology & Inflammation Summit (Virtual) - fireside chat on Wednesday, November 12, 2025, at 11:30 a.m. ET 2025 Jefferies Global Healthcare Conf ...

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, its Prime Edi ...

Key Takeaways CorMedix's DefenCath drives strong 2025 revenue growth and profitability after expanded U.S. market adoption.The Melinta acquisition adds seven approved drugs, expanding CorMedix's hospital and infection focus.Theravance leans on Viatris for Yupelri sales while advancing late-stage ampreloxetine for nOH MSA.In the competitive world of small-cap biotechnology, CorMedix (CRMD) and Theravance Biopharma (TBPH) stand out as two companies working to turn scientific progress into lasting profits. Bot ...

The biotech sector has faced a challenging first half of 2025, underperforming relative to the broader tech industry and the S&P 500. Nonetheless, there has been a strong rebound in the second half of 2025, particularly among profitable biotechs, following a significant increase in merger and acquisition (M&A) activity in the XBI index, said Aditya Kotta, head of business development of US and EU at global contract research organisation (CRO) Novotech at a recent conference. Kotta said that the bounce ba ...

Right now ahead of Halloween, the real suspense might be in ETF investing strategies. With markets seesawing between hopes for rate cuts and the resilience of earnings, investors are dusting off one of Wall Street’s spooky old sayings:  Sell in May and go away.The so-called Halloween Effect, a pattern where stocks outperform between November and April, might sound like folklore. But the data has teeth. Yardeni Research’s historical analysis of the S&P 500 shows that from 1928 to 2025, returns averaged 5.2% ...